Litcius/Paper detail

Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency

Daniel J. Smith, Paul Ellis, Alice Turner

2020Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation16 citationsDOIOpen Access PDF

Abstract

Alpha-1 antitrypsin deficiency (AATD) is an important risk factor for development of chronic obstructive pulmonary disease (COPD). Patients with AATD classically develop a different pattern of lung disease from those with usual COPD, decline faster and exhibit a range of differences in pathogenesis, all of which may be relevant to phenotype and/or impact of exacerbations. There are a number of definitions of exacerbation, with the main features being worsening of symptoms over at least 2 days, which may be associated with a change in treatment. In this article we review the literature surrounding exacerbations in AATD, focusing, in particular, on ways in which they may differ from such events in usual COPD, and the potential impact on clinical management.

Topics & Concepts

Alpha 1-antitrypsin deficiencyCOPDPathogenesisPulmonary diseaseMedicineDiseaseLungAlpha (finance)Lung diseaseRisk factorImmunologyIntensive care medicineInternal medicineSurgeryConstruct validityPatient satisfactionProtease and Inhibitor MechanismsPeptidase Inhibition and AnalysisPulmonary Hypertension Research and Treatments
Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency | Litcius